Zynerba Pharmaceuticals, Inc.
DelistedCIK 1621443fmd_06V8KGMN6M5Z72N8ZQVDEMD12QManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Jun 30, 2023, 39 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 1 | 0 | 0 | 0 | 0 | – | – | – | – |
| Net interest income | (0) | (0) | 0 | 0 | – | – | – | – | – | – |
| Research and development | 1 | 2 | 7 | 17 | 23 | 27 | 20 | 36 | 21 | 21 |
| Total operating expenses | 2 | 6 | 13 | 23 | 33 | 40 | 34 | 52 | 37 | 35 |
| Operating income | (1) | (6) | (13) | (23) | (33) | (40) | (34) | (52) | (37) | (35) |
| Other non-operating income (expense) | – | (0) | 0 | (0) | 1 | 0 | 1 | 1 | (1) | 0 |
| Income before taxes | (1) | (6) | (13) | (23) | (32) | (40) | (33) | (51) | (37) | (35) |
| Income tax expense | – | – | 0 | (0) | 0 | 0 | – | – | – | – |
| Net income from continuing operations | – | – | (13) | (23) | (32) | (40) | – | – | – | – |
| Net income | (1) | (6) | (13) | (23) | (32) | (40) | (33) | (51) | (37) | (35) |
| Net income to common shareholders | (1) | (6) | (13) | (23) | (32) | (40) | (33) | (51) | (37) | (35) |